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Epidemiological and genetic data support the notion that schizophrenia and bipolar disorder share genetic risk factors. In our
previous genome-wide association study, meta-analysis and follow-up (totaling as many as 18 206 cases and 42 536 controls), we
identified four loci showing genome-wide significant association with schizophrenia. Here we consider a mixed schizophrenia and
bipolar disorder (psychosis) phenotype (addition of 7469 bipolar disorder cases, 1535 schizophrenia cases, 333 other psychosis
cases, 808 unaffected family members and 46 160 controls). Combined analysis reveals a novel variant at 16p11.2 showing genome-
wide significant association (rs4583255[T]; odds ratio¼ 1.08; P¼ 6.6 10 11). The new variant is located within a 593-kb region
that substantially increases risk of psychosis when duplicated. In line with the association of the duplication with reduced body
mass index (BMI), rs4583255[T] is also associated with lower BMI (P¼ 0.0039 in the public GIANT consortium data set; P¼ 0.00047 in
22 651 additional Icelanders).
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INTRODUCTION
Two structural variants, a balanced t(1;11) translocation interrupt-
ing DISC1 and a microdeletion at 22q11.2, were the first genetic
polymorphisms to show compelling evidence of association with
schizophrenia.1,2 More recently, additional microdeletions and
microduplications conferring risk of schizophrenia and, in some
cases, bipolar disorder have been uncovered.3–10 These copy
number variants (CNVs) confer high-to-moderate relative risk,
however, because they typically change copy number of multiple
genes, and may also affect regulation of genes at their margins,
they do not generally implicate individual genes.
Currently, common single nucleotide polymorphisms (SNPs) are
convincing risk factors for schizophrenia and bipolar disorder, in
addition to structural variants. Common alleles showing genome-
wide significant association with at least one of the disorders have
been found at more than 20 loci.11–29 None of these regions are
within structural polymorphisms previously shown to be suscep-
tibility factors for schizophrenia or bipolar disorder. Nevertheless,
first principles and data from other disorders predict the existence
of common variants conferring risk through the same genes as
rare structural alleles.30 The identification of common risk variants
within CNV regions may aid in uncovering the causal gene or
genes of a CNV, or help to elucidate other aspects of a CNV’s
association with disease.
Two loci have been reported to harbor common alleles showing
genome-wide significant association with both schizophrenia and
bipolar disorder.13,16,23,24 In addition, several common variants
initially displaying genome-wide significant association with one
of the disorders have been shown, in subsequent studies, to
confer risk of the other.31,32 Investigations considering schizo-
phrenia and bipolar disorder as a single phenotype also support
shared risk alleles,16,19,22 and an overlapping polygenetic compo-
nent has been described by several studies.21,28 These data are
consistent with current epidemiological investigations, which predict
shared genetic risk factors for schizophrenia and bipolar disorder.33
Previously, we carried out a schizophrenia genome-wide
association (GWA) study, SGENE-plus, followed by meta-analysis
of the top 1500 results with data from the International
Schizophrenia Consortium (ISC) and the Molecular Genetics of
Schizophrenia (MGS) group.15 Loci having P-values o1 10 4
(covered by 39 SNPs located in 33 genomic regions) were
followed up in a data set of up to 10 260 schizophrenia cases and
23 500 controls.14 In this work, we broaden our phenotype of
interest to psychosis (schizophrenia, bipolar disorder and related
psychoses), examining the same group of follow-up SNPs in a data
set augmented by 7469 bipolar disorder cases, 1535 schizophrenia
cases, 333 other psychosis cases, 808 unaffected family members
and 46 160 controls.
MATERIALS AND METHODS
Samples
The genome-wide typed (‘SGENE-plus’; 2663 cases and 13 498 controls)
and meta-analysis (‘SGENE-plusþ ISCþMGS’) samples (in total, 7946 cases
and 19 036 controls) used here were identical to those used in our previous
schizophrenia GWA study and meta-analysis.15 The primary psychosis
follow-up samples employed consisted of follow-up samples from our
previous GWA follow-up study (9246 schizophrenia cases and 22 356
controls),14 plus an additional 9337 psychosis cases (1535 schizophrenia,
7469 bipolar disorder and 333 related psychoses) and 46 968 controls/
unaffected family members. The primary follow-up samples were
genotyped or imputed for all follow-up markers. The secondary follow-
up samples consisted of 1014 cases and 1144 controls from the Go¨ttingen
Research Association for Schizophrenia34,35 study. These samples, which
also had been used for secondary follow-up in our previous GWA follow-up
study,14 were genotyped for SNPs that were genome-wide significant in
the combined meta-analysis and primary follow-up samples. Table 1
summarizes the schizophrenia and psychosis data sets used in previous
and current work, and Supplementary Table 1 includes details on the
individual study groups. The autism samples (3773 cases, 16 103 controls,
4206 family members) derived from the Autism Genome Project, the
Autism Genetic Resource Exchange and nine European study groups
(Supplementary Table 2). Further information on ascertainment and
diagnosis for the psychosis and autism samples is provided in the
Supplementary Material.
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Genotyping and association analysis
Genotyping was carried out using Illumina (San Diego, CA, USA) and
Affymetrix genome-wide arrays (Santa Clara, CA, USA), Nanogen (San
Diego, CA, USA) Centaurus assays, Taqman assays, the Sequenom
MassArray iPLEX genotyping system (San Diego, CA, USA) and the Roche
LightCycler480 system (Mannheim, Germany) (Supplementary Tables 1
and 2). Quality control and imputation were performed, by study group, as
described in the Supplementary Methods. Case–control or family-based
association analyses were carried out for each study group. For the case–
control analyses, population stratification was controlled for using genomic
control or principal components. Summary statistics from the various study
groups were combined as described previously.15 Body mass index (BMI)
measurements were adjusted for age and sex, and inverse standard
normal transformed. Analysis was carried out by regressing the adjusted,
transformed data on rs4583255[T] count.
Expression analysis
For the three brain data sets,36–38 expression levels were inverse normal
transformed and regressed on the number of rs4583255-T alleles with
gender, age at death, post-mortem interval, brain source, expression
experiment batch, pH (Colantuoni et al.36 only), sample expression level
based on the total number of transcripts detected (Webster et al.38 only)
and Alzheimer’s disease patient status (Webster et al.38 only) as covariates.
To incorporate data from different brain regions (Gibbs et al.37) or different
probes (KCTD13 in Colantuoni et al.36) derived from the same individual, a
mixed-effects model with individual as a random effect was used. Results
from the three data sets were combined using inverse-variance weighted
meta-analysis. The Dutch whole-blood data set included control samples
from two studies.39,40 Analysis was performed using linear regression in
Plink41 taking age and gender as covariates. The Icelandic blood data set
has been described previously,42 and analysis was carried out as detailed in
that work.42
RESULTS
We assembled a psychosis (schizophrenia, bipolar disorder and
related psychoses) primary follow-up data set made up of 36 study
groups containing a total of 18 583 cases, 68 516 controls and 808
unaffected family members (Supplementary Table 1). In each
study group, allelic association analysis was carried out for 39 SNPs
from 33 genomic regions (these SNPs covered P-values
o1 10 4 in the SGENE-plusþ ISCþMGS meta-analysis at
r2¼ 0.3). Results from the various study groups were combined
using inverse-variance weighted meta-analysis.
At 31 of the 33 loci, odds ratios (ORs) in the psychosis follow-up
group were in the same direction as in the discovery data set
(SGENE-plusþ ISCþMGS) (Supplementary Table 3). A similar
pattern had been observed in the schizophrenia follow-up set—
ORs were in the same direction at 30 of the 33 loci.14 These results
indicate that the set of variants chosen for follow-up was enriched
for risk alleles (P¼ 7.0 10 7 for schizophrenia; P¼ 6.5 10 8
for psychosis).
Next, we performed a joint analysis of the discovery and
psychosis follow-up sets. To account for testing two phenotypes
(schizophrenia and psychosis), the genome-wide significance
threshold was set at Po(5 10 8)/2, or 2.5 10 8. Five SNPs,
residing at three loci, exceeded this threshold (Supplementary
Table 3). Two of the loci—the major histocompatibility complex
region and 11q21.2 near NRGN—had been genome-wide
significant in the previous schizophrenia analysis; a third locus,
in TAOK2 at 16p11.2, was novel (Supplementary Table 3).
Following the addition of data from a further 1014 schizophrenia
cases and 1144 controls, the variant at the novel locus,
rs4583255[T], was associated with psychosis with increased
significance (OR¼ 1.08, P¼ 6.6 10 11, Table 2, Figure 1).
rs4583255[T]’s association with psychosis fit the multiplicative
model (P¼ 0.42), and there was no evidence of OR heterogeneity
(P¼ 0.71; I2¼ 0; Supplementary Table 4).
In examination of the follow-up samples by diagnosis, the novel
variant, rs4583255[T], showed significant association with both
schizophrenia and bipolar disorder (P¼ 0.0011 and 0.00026,
respectively), with OR of 1.06 and 1.08, respectively (independent
controls were used for the two analyses; see Supplementary
Table 5). We also investigated association with bipolar disorder for
variants that had shown genome-wide significant association with
schizophrenia in our previous study.14 Following correction for
eight tests, rs12807809[T], near NRGN, was significantly associated
with bipolar disorder (P¼ 0.0023) with an OR identical to that of
the schizophrenia follow-up samples (OR¼ 1.09). The remaining
schizophrenia susceptibility variants did not show even nominally
significant association with bipolar disorder—yet, OR confidence
intervals for the two disorders overlapped for at least some
variants at all loci (Supplementary Table 5).
Intriguingly, the newly identified SNP is located in a nearly 600-
kb region that confers risk of schizophrenia and bipolar disorder
when duplicated (Figure 1).5,6,28 Copy number gain of the region
also is associated with autism,6,43–45 reduced head circumfer-
ence46,47 and low BMI.47 We obtained large data sets to
examine association of rs4583255[T] with both autism and BMI.
Based on 3773 cases, 16 103 controls and 4206 unaffected family
members from the Autism Genetic Resource Exchange, the Autism
Genome Project and nine European study groups (Supplementary
Table 2), we found no evidence of association with autism
spectrum disorder (ASD), strict autism or multiplex ASD (ASD,
OR¼ 1.00, P¼ 0.98; strict autism, OR¼ 1.02, P¼ 0.66; multiplex
ASD, OR¼ 1.07, P¼ 0.22; Supplementary Table 6), although power
Table 1. Schizophrenia and psychosis data sets used in previous and current work
Data set Case phenotype Markers
examined
N Initial use Overlap with other sets
Cases Controls þ family
members
SGENE-plus GWAS SZ 314 868 2663 13 498 Stefansson15 No
SGENE-
plusþ ISCþMGS
SZ 1500 7946 19 036 Stefansson15 Includes SGENE-plus GWAS
Primary schizoprenia
follow-up
SZ 39 9246 22 356 Steinberg14 No
Primary psychosis
follow-up
SZ, BP, other
psychosis
39 18 583 69 324 This work Includes primary schizophrenia
follow-up
Secondary follow-up SZ 8; 1a 1014 1144 Steinberg14 No
Abbreviations: BP, bipolar disorder; GWAS, genome-wide association study; ISC, International Schizophrenia Consortium; MGS, molecular genetics of
schizophrenia; SZ, schizophrenia.
aEight markers were examined in this set in the previous work,14 and an additional marker is genotyped in the current work.
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to detect association at the OR found in the follow-up
psychosis samples was modest (at a 0.05 significance level, power
was about 57% for ASD, 42% for strict autism and 23% for
multiplex ASD). In contrast, we found significant association
of rs4583255[T] with lower BMI in the published GIANT consortium
GWAS data set of 123 865 individuals48 (P¼ 0.0039) and in 22 651
Icelanders who were not included in the GIANT study
(P¼ 0.00047).
Recently, a study examining the effect of altered expression of
16p11.2 CNV region genes on zebrafish head size identified
KCTD13 as the major driver of head size change, with MAPK3 and
MVP named as possible modifiers.49 These results motivated us to
examine association of rs4583255[T] with expression of KCTD13,
MAPK3 and MVP in human brain. Using data from three publicly
available data sets with at least 50 European-ancestry adult brains
each (total N¼ 565),36–38 we found that rs4583255[T] was
significantly associated with expression of MAPK3 (effect¼ 0.12
s.d.; P¼ 0.011), but not significantly associated with expression of
KCTD13 or MVP (Supplementary Table 7). We also investigated
association of rs4583255[T] with gene expression in blood using
data sets from Iceland (N¼ 972)42 and the Netherlands
(N¼ 437).39,40 Consistent with the brain results, rs4583255[T] was
significantly associated with higher expression of MAPK3 (for
Iceland, P¼ 9.4 10 15; for the Netherlands, P¼ 0.014 for probe
3870601, and P¼ 0.042 for probe 234040), but not significantly
associated with expression of KCTD13 or MVP.
DISCUSSION
In this study, we uncovered a novel variant at 16p11.2,
rs4583255[T], showing genome-wide significant association with
psychosis (OR¼ 1.08; P¼ 6.6 10 11). In follow-up samples, ORs
were similar for schizophrenia and bipolar disorder (OR¼ 1.06 and
1.08, respectively), and association was significant for both
(P¼ 0.0011 and 0.00026, respectively). Thus, rs4583255[T] is a
compelling example of a genetic variant that confers risk across
traditional diagnostic boundaries.
Among the variants that showed genome-wide significant
association with schizophrenia in our previous study,14 only
rs12807809[T] showed significant association with bipolar disorder
in the current work. Nevertheless, OR confidence intervals for
schizophrenia and bipolar disorder overlapped for most risk
alleles. Very large data sets will be necessary to establish
conclusively where these variants fall on the spectrum of
conferring risk of one disorder, exclusively, to conferring equal
risk of either.
To our knowledge, this is the first case in which a common risk
allele showing genome-wide significant association with psychosis
has turned out to be located within a CNV that had been
previously associated with psychosis. Both copy number gain and
loss of the 16p11.2 region are associated with multiple
phenotypes. Duplication is associated with psychosis,5,6,28 both
copy number gain and loss are associated with autism and
developmental delay,6,43–45 and duplication and deletion lead to
Table 2. Genome-wide significant association of rs4583255[T] with psychosis
Study group N OR (95% CI) P-value
Cases Controls Family members
SGENE-plusþ ISCþMGS 7946 19 036 0 1.10 (1.05, 1.15) 2.5 10 5
Primary psychosis follow-up 18 583 68 516 808 1.07 (1.04, 1.10) 9.2 10 7
Secondary follow-up 1014 1144 0 1.10 (0.97, 1.24) 0.14
Combined 27 543 88 696 808 1.08 (1.05, 1.10) 6.6 10 11
Abbreviations: CI, confidence interval; ISC, International Schizophrenia Consortium; MGS, Molecular Genetics of Schizophrenia; OR, odds ratio.
Figure 1. Association results and structure of the 16p11.2 region. Bars on the x-axis indicate segmental duplications (brown) and
recombination hotspots (pink). Association results are illustrated for SGENE-plus (black), SGENE-plusþMGSþ ISC (green), SGENE-plusþ
MGSþ ISC plus the primary psychosis follow-up (blue) and SGENE-plusþMGSþ ISC plus the primary psychosis and secondary schizophrenia
follow-up (red). RefSeq genes in the region are shown below the plot.
Psychosis variant at 16p11.2
S Steinberg et al
111
& 2014 Macmillan Publishers Limited Molecular Psychiatry (2014), 108 – 114
reduction and enlargement, respectively, of head circumference
and BMI.46,47
In this work, we found that rs4583255[T] also confers risk of
reduced BMI (P¼ 0.0039 in GIANT; P¼ 0.00047 in additional
Icelanders). This result supports the suggestion, made pre-
viously,47 that the effects of duplication on psychosis and BMI
have a single origin, presumably in the brain. We did not find
evidence of association of rs4583255[T] with autism, although we
were somewhat underpowered to detect an effect of the same
size as in psychosis, especially, for sub-phenotypes.
We found that rs4583255[T] was associated with increased
expression in adult brain and blood of MAPK3, one of the 16p11.2
genes identified as involved in causing head-circumference
changes in zebrafish.49 Caution is required in interpretation of
this result, however, as the significance in brain is not over-
whelming and, furthermore, gene expression in the pre-adult
brain may be most relevant for the development of psychosis.
Data from only extremely small numbers of European-ancestry
brains at pre-adult stages were available, precluding investigation
of the association of rs4583255[T] with gene expression at these
stages.
In conclusion, in this work, we broadened our phenotype of
interest to psychosis, identifying a new common risk allele,
rs4583255[T], with similar ORs for schizophrenia and bipolar
disorder. The novel variant is located within a duplication
previously associated with psychosis, and, in line with the
duplication’s effects, also is associated with lower BMI. In the
future, knowledge of this common variant association may prove
useful to studies aimed at further understanding the mechanism
through which the duplication exerts its effects on neurodevelop-
mental and anthropomorphic phenotypes.
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